DNA RNA and Cells

31 Jan 2017 ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach
31 Jan 2017 TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis
30 Jan 2017 uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B
30 Jan 2017 Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital
26 Jan 2017 SpinalCyte, LLC Enrolls First Patient in Landmark Phase I Human Clinical Trial
25 Jan 2017 Oncolytic Viruses: a still undervalued technology with strong growth perspectives
23 Jan 2017 Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions
23 Jan 2017 MOLOGEN AG: Combination data of TLR9 agonist lefitolimod with checkpoint inhibitors in preclinical tumor models
23 Jan 2017 Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
18 Jan 2017 Lysogene Receives Rare Pediatric Disease Designation from FDA for LYS-GM101 for Treatment of GM1 Gangliosidosis
18 Jan 2017 Servier appoints MaSTherCell for the development of its CAR-T cell therapy manufacturing platform
18 Jan 2017 Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
14 Jan 2017 New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
13 Jan 2017 Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
12 Jan 2017 CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference
09 Jan 2017 Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
09 Jan 2017 Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
09 Jan 2017 The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
07 Jan 2017 Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer
07 Jan 2017 Allele to Develop iPSC-Derived Cell Therapies with Focus on Diabetes and Spinal Cord Injury
05 Jan 2017 Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A
04 Jan 2017 Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection
04 Jan 2017 Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
04 Jan 2017 Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN
03 Jan 2017 Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing